Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

ClinicalTrials.gov ID: NCT03309111

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03309111. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 4:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, First-in-Human, Multicenter, Open-Label, Two-Part Dose-Escalation and Cohort Expansion Study of Single-Agent ISB 1342 in Subjects With Previously Treated Multiple Myeloma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK)/pharmacodynamic (PD), and immunogenicity with ISB 1342 in subjects with relapsed/refractory multiple myeloma.

Study identification

NCT ID
NCT03309111
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Ichnos Sciences SA
Industry
Enrollment
81 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 25, 2017 (Actual)
Primary completion
Dec 15, 2023 (Actual)
Completion
Dec 15, 2023 (Actual)
Last update posted
Jun 13, 2024

2017 – 2023

United States locations

U.S. sites
9
U.S. states
7
U.S. cities
7
Facility City State ZIP Site status
Colorado Blood Cancer Institute Denver Colorado 80218 —
Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland 21287 —
Mayo Clinic Cancer Center (MCCC) - Rochester Rochester Minnesota 55905 —
Hackensack University Medical Center Hackensack New Jersey 07601 —
Mount Sinai Beth Israel New York New York 10029 —
Memorial Sloan-Kettering Cancer Center New York New York 10065 —
Duke Clinical Research Institute Durham North Carolina 72205 —
Tennessee Oncology Nashville Tennessee 37203 —
Vanderbilt University Medical Center Nashville Tennessee 37232 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03309111, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 13, 2024 · Synced Nov 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.